Most Viewed Articles

Rare Benign and Uncertain Malignant Potential Tumors of Bladder: Review of the Literature
  • Cem Yücel
  • Mehmet Zeynel Keskin
Bull Urooncol 2017; 16: 123-126 DOI: 10.4274/uob.673
Neutropenic Fever, Skin and Eye Toxicities Develops During Docetaxel Treatment in Metastatic Prostate Cancer: A Case Report
  • Erdem Şen
  • İrem Öner
  • Özlem Ata
Bull Urooncol 2017; 16: 133-136 DOI: 10.4274/uob.908
Is Preoperative Neutrophil Lymphocyte Ratio a Reliable Prognostic Parameter for Localized Prostate Cancer?
  • Tümay İpekçi
  • Mustafa Yüksel
  • Murat Uçar
  • Ahmet Tunçkıran
  • Zafer Kozacıoğlu
  • Ramazan Yavuz Akman
Bull Urooncol 2017; 16: 119-122 DOI: 10.4274/uob.900
Evaluation of the Relationship Between Duration of Smoking and Clinical and Pathologic Characteristics of Bladder Cancer at Diagnosis
  • Bora İrer
  • Filiz Dağ
  • Güven Aslan
Bull Urooncol 2017; 16: 108-111 DOI: 10.4274/uob.870
Determination of Six Transmembrane Protein of Prostate 2 Gene Expression and Intracellular Localization in Prostate Cancer
  • Bora İrer
  • Ömer Demir
  • Aykut Kefi
  • Güven Aslan
Bull Urooncol 2017; 16: 112-118 DOI: 10.4274/uob.890
Active Surveillance in Prostate Cancer
  • Volkan İzol
  • Nebil Akdoğan
Bull Urooncol 2017; 16: 127-132 DOI: 10.4274/uob.820
2017 Author Index
Bull Urooncol 2017; 16: 0-0
2017 Subject Index
Bull Urooncol 2017; 16: 0-0
Editorial
  • Murat Koşan
Bull Urooncol 2017; 16: 0-0
A Rare Presentation of Germ Cell Neoplasia: Persistant Müllerian Duct Syndrome
  • Alp Tuna Beksaç
  • Muhammet Irfan Dönmez
  • Çisel Aydın
  • Dilek Ertoy Baydar
  • Mustafa Sertaç Yazıcı
  • Ali Ergen
  • Bülent Akdoğan
Bull Urooncol 2017; 16: 101-104 DOI: 10.4274/uob.825
2017 Referee Index
Bull Urooncol 2017; 16: 0-0
Preoperative Factors Related to Stage and Grade Increase in D’Amico Low-Risk and Intermediate-Risk Group Patients
  • Serdar Çelik
  • Ozan Bozkurt
  • Ömer Demir
  • Burçin Tuna
  • Kutsal Yörükoğlu
  • Güven Aslan
Bull Urooncol 2016; 15: 148-153 DOI: 10.4274/uob.738
The Relationship between Bladder Cancer and Epigenetic Alterations
  • Ata Özen
  • Ali Ülgen
  • Cavit Can
Bull Urooncol 2017; 16: 17-21 DOI: 10.4274/uob.566
What are the New Developments in Urinary, Serum and Tissue Biomarkers in Prostate Cancer?
  • Hayrettin Şahin
  • Mehmet Çetinkaya
  • Hasan Deliktaş
Bull Urooncol 2017; 16: 95-100 DOI: 10.4274/uob.620
Relationship Between Human Papilloma Virus and Bladder Cancer
  • Osman İnci
  • Ebru Taştekin
  • Hakan Akdere
Bull Urooncol 2017; 16: 92-94 DOI: 10.4274/uob.556
Do Length and Tumor Grades of Positive Surgical Margin Have an Impact on Biochemical Recurrence After Prostatectomy?
  • Murat Yavuz Koparal
  • Cenk Acar
  • Betül Ögüt
  • Eda Tokat
  • Fatih Bıçaklıoğlu
  • İpek Işık Gönül
  • Ali Furkan Batur
  • Tevfik Sinan Sözen
Bull Urooncol 2017; 16: 86-91 DOI: 10.4274/uob.859
Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer
  • Zeliha Ertürk
  • Esra Büber
  • Haluk Özen
  • Ömür Çelikbıçak
  • Bekir Salih
  • N. Leyla Açan
Bull Urooncol 2017; 16: 70-76 DOI: 10.4274/uob.905
The Risk Stratifications in Non-Muscle Invasive Bladder Cancer: How Much Accurate are the Methods That We Use? A Multi-Directional View
  • Barış Kuzgunbay
  • Yıldırım Bayazıt
Bull Urooncol 2015; 14: 18-22 DOI: 10.4274/uob.275
Initial Outcomes and Assessment of the Transperineal Multiparametric-Magnetic Resonance Imaging/Ultrasonography Fusion Biopsy Method in Diagnosing Clinically-significant Prostate Cancer
  • Mahir B. Özgen
  • Bora Özveren
  • Sertaç Uzel
  • Uğur Altuğ
  • Levent Türkeri
Bull Urooncol 2017; 16: 42-45 DOI: 10.4274/uob.805
The Effect of Sex and Age Differences on Pathology Results in Primary Bladder Cancer Patients
  • Hakan Türk
  • Sıtkı Ün
  • Batuhan Ergani
Bull Urooncol 2017; 16: 81-85 DOI: 10.4274/uob.857
Risk Adaptive Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
  • Elif Atağ
  • Aziz Karaoğlu
  • Ömer Küçük
Bull Urooncol 2017; 16: 57-62 DOI: 10.4274/uob.763
The Efficiency of Docetaxel Chemotherapy on Castration Resistant Prostate Cancer: Singe Center Experience
  • Evren Süer
  • Nurullah Hamidi
  • Mehmet İlker Gökçe
  • Sümer Baltacı
Bull Urooncol 2017; 16: 77-80 DOI: 10.4274/uob.821
Gleason Score Correlation Between Prostate Biopsy and Radical Prostatectomy Specimens
  • Erdem Öztürk
  • Taha Numan Yıkılmaz
Bull Urooncol 2018; 17: 1-4 DOI: 10.4274/uob.921
Testicular Microlithiasis An...
  • Oguz Özden Cebeci
  • Levent Özcan
Bull Urooncol 2015; 14: 232-234 DOI: 10.4274/uob.414
Primary Adrenal Lymphoma: A Case Report
  • İlke Onur Kazaz
  • Ayhan Arslan
  • Nergiz Erkut
  • Ömer Kutlu
Bull Urooncol 2017; 16: 105-107 DOI: 10.4274/uob.876
The Expression Frequency of Androgen Receptor, c-erbB2 and CD117 in Acinar Adenocarcinoma of Prostate and Normal Prostate Tissue and It’s Clinical Importance
  • Hülya Savaş Mutlu
  • Oğuz Aydın
  • Sancar Barış
  • Sevgi Canbaz
  • Filiz Karagöz
Bull Urooncol 2015; 14: 245-250 DOI: 10.4274/uob.376
Geometry of cancer and fractals in bladder cancer
  • Fehmi Narter
  • Osman Köse
Bull Urooncol 2013; 12: 11-17
Genetik alteration in bladder carcinoma
  • Hakan Akça
  • Onur Tokgün
Bull Urooncol 2012; 11: 10-13
Effects and Mechanisms of Checkpoint Inhibitors (CTLA-4, PD-1 and PD-L1 Inhibitors) as New Immunotherapeutic Agents for Bladder Cancer
  • Serdar Çelik
  • Zekiye Sultan Altun
  • Safiye Aktaş
Bull Urooncol 2018; 17: 18-25 DOI: 10.4274/uob.947
Society of Urooncology nomogram for kidney cancer – the user's manual
  • Özgür Yaycıoğlu
Bull Urooncol 2013; 12: 151-154
Defining the ideal patient for active surveillance in localized prostate cancer and the impact of active surveillance studies on clinical practice
  • Ayhan Dirim
  • Hakan Özkardeş
Bull Urooncol 2011; 10: 41-46
Editorial
  • Murat Koşan
Bull Urooncol 2017; 16: 0-0
Non-Muscle Invasive Bladder Cancer: Diagnosis and Treatment of Highest-Risk Subgroup
  • Yılören Tanıdır
  • İlker Tınay
Bull Urooncol 2015; 14: 50-54 DOI: 10.4274/uob.298
Ongoing Studies of the Bladder Tumor Study Group: An Overview
  • N. Aydın Mungan
  • İlker Tınay
Bull Urooncol 2014; 13: 67-69 DOI: 10.4274/UOB.01
Transurethral Resection of Bladder Cancer (TUR-B) for Non-Muscle Invasive Bladder Cancer: How to Reach Excellence?
  • Mehmet İlker Gökçe
  • Yaşar Bedük
Bull Urooncol 2014; 13: 88-92 DOI: 10.4274/UOB.06
Do the Pain Scores During Transrectal Ultrasound-guided Prostate Rebiopsy Change in Patients with a Prior History of Prostate Biopsy?
  • Dr. Deniz Bolat
  • Dr. Mehmet Erhan Aydın
  • Dr. Bülent Günlüsoy
  • Dr. Tansu Değirmenci
  • Dr. Yusuf Kadir Topçu
  • Dr. İbrahim Küçüktürkmen
  • Dr. Zafer Kozacıoğlu
Bull Urooncol 2017; 16: 4-7 DOI: 10.4274/uob.784
BCG komplikasyonları ve başa çıkma
  • Uğur Yücetaş
  • Gökhan Toktaş
Bull Urooncol 2011; 10: 23-25
Molecular Biology in Diagnosis and Treatment of Prostate Cancer
  • Ece Konaç
  • Sinan Sözen
Bull Urooncol 2014; 13: 228-235 DOI: 10.4274/uob.194
Paratesticular Tumors and Clinicopathologic Approach
  • Kemal Behzatoğlu
  • Ceren Boyacı
  • Buket Bambul Sığırcı
Bull Urooncol 2015; 14: 271-277 DOI: 10.4274/uob.481
Radiological methods that aid in the diagnosis of bladder cancer
  • Fatih Kantarcı
  • Deniz Çebi Olgun
  • Atilla Süleyman Dikici
Bull Urooncol 2013; 12: 54-57
Does inhibition of inflammation help in preventing prostate cancer ?
  • Ali İhsan Arık
  • Ahmet Güdeloğlu
  • Cemil Uygur
Bull Urooncol 2011; 10: 22-26
Incidentally Found Paratesticular Rhabdomyosarcoma: Case Report
  • Halil Çağrı Aybal
  • Taha Numan Yıkılmaz
  • Fatih Hızlı
  • Halil Başar
  • Emin Taha Keskin
Bull Urooncol 2017; 16: 28-30 DOI: 10.4274/uob.720
‘Nanotechnology Applications’ in the Treatment of Prostate Cancer
  • Ali Furkan Batur
  • Kerem Gencer Kutman
  • Mustafa Suat Bolat
Bull Urooncol 2015; 14: 150-155 DOI: 10.4274/uob.375
Relationship between active surveillance / watchfull waiting and quality of life in localised prostate cancer
  • İlker Çelen
  • Yasin Ceylan
Bull Urooncol 2013; 12: 123-126
Bladder cancer and genetics
  • Ata Özen
  • Cavit Can
Bull Urooncol 2013; 12: 36-42
Nursing care following radical cystectomy and urinary diversion
  • Cemile Ulubay Akkaya
Bull Urooncol 2013; 12: 43-45
Experimental Bladder Cancer Models for Animals
  • Murat Koşan
  • Aydın Mungan
Bull Urooncol 2015; 14: 29-32 DOI: 10.4274/uob.283
Metastasis Targeted Therapies in Renal Cell Cancer
  • K. Fehmi Narter
  • Bora Özveren
Bull Urooncol 2018; 17: 26-32 DOI: 10.4274/uob.962
What is the current status of bladder tumor markers?
  • İbrahim Dönmez
  • N. Aydın Mungan
Bull Urooncol 2012; 11: 19-26
Second-TUR
  • Ali Feyzullah Şahin
  • Rauf Taner Divrik
Bull Urooncol 2013; 12: 18-21

About Journal

Forms

Useful Links

Applications